View in EDS HTML Full Text PDF Full Text

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.

Saved in:
Bibliographic Details
Title: Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
Authors: Liu, Dan1 (AUTHOR), Zhou, Jun2 (AUTHOR), Wang, Yongsheng3 (AUTHOR), Li, Mingjun4 (AUTHOR), Jiang, Haiping5 (AUTHOR), Liu, Yunpeng6 (AUTHOR), Yin, Xianli7 (AUTHOR), Ge, Minghua8 (AUTHOR), Xiang, Xiaojun9 (AUTHOR), Ying, Jieer10 (AUTHOR), Huang, Jian11 (AUTHOR), Zhang, Yan-qiao12 (AUTHOR), Cheng, Ying13 (AUTHOR), Huang, Zhigang14 (AUTHOR), Yuan, Xianglin15 (AUTHOR), Han, Weiqing16 (AUTHOR), Yan, Dong17 (AUTHOR), Wang, Xinshuai18 (AUTHOR), Liu, Pan19 (AUTHOR), Wang, Linna19 (AUTHOR)
Source: BMC Medicine. 10/24/2022, Vol. 20 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17417015
DOI:10.1186/s12916-022-02605-9